Study 06-008
Assessed for Eligibility: \( n = 1853 \)

<table>
<thead>
<tr>
<th>SXB</th>
<th>PBO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>365</td>
<td>183</td>
<td>548</td>
</tr>
</tbody>
</table>

- Discontinued: 142, 72, 214 (39%)
- Adverse Events: 21%, 11%, 18%
- Lack of Efficacy: 7%, 16%, 10%
- Withdrawn Consent: 4%, 6%, 7%
- Other: 4%, 6%, 5%

Completed: 223, 111, 334 (61%)

Enrolled in 06-010*: 183, 86, 269 (82%)

Study 06-009
Assessed for Eligibility: \( n = 1544 \)

<table>
<thead>
<tr>
<th>SXB</th>
<th>PBO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>385</td>
<td>188</td>
<td>573</td>
</tr>
</tbody>
</table>

- Discontinued: 140, 57, 197 (36%)
- Adverse Events: 18%, 6%, 14%
- Lack of Efficacy: 10%, 12%, 10%
- Withdrawn Consent: 3%, 3%, 3%
- Other: 5%, 9%, 6%

Completed: 245, 131, 376 (64%)

Enrolled in 06-010*: 191, 101, 292 (78%)

Study 06-010
Assessed for Eligibility*: \( n = 561 \) (79%)

| Prior Study Treatment
<table>
<thead>
<tr>
<th>SXB</th>
<th>PBO</th>
<th>Total*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated</td>
<td>374</td>
<td>186</td>
</tr>
</tbody>
</table>

- Discontinued: 150, 91, 241 (40%)
- Adverse Events: 21%, 27%, 23%
- Lack of Efficacy: 6%, 9%, 7%
- Withdrawn Consent: 7%, 6%, 6%
- Lost to Follow-up: 3%, 2%, 3%
- Investigator Decision: 2%, 1%, 1%
- Protocol Deviation/Violation: 1%, 1%, 1%
- Other: 1%, 1%, 1%
- Sponsor Decision: 0%, 2%, 1%

Completed: 224, 95, 319 (60%)

Enrolled in 06-010*: 191, 101, 292 (78%)

Prior Study Treatment
<table>
<thead>
<tr>
<th>SXB</th>
<th>PBO</th>
<th>Total</th>
</tr>
</thead>
</table>
| Discontinued: 150, 91, 241 (40%)
- Adverse Events: 21%, 27%, 23%
- Lack of Efficacy: 6%, 9%, 7%
- Withdrawn Consent: 7%, 6%, 6%
- Lost to Follow-up: 3%, 2%, 3%
- Investigator Decision: 2%, 1%, 1%
- Protocol Deviation/Violation: 1%, 1%, 1%
- Other: 1%, 1%, 1%
- Sponsor Decision: 0%, 2%, 1%